Haleos Labs Limited Ratios

Haleos Labs Limited Ratios

The Haleos Labs Limited Ratios page provides a complete fundamental analysis of Haleos Labs Limited using key valuation, profitability, and financial strength metrics. Investors tracking Haleos Labs Limited Ratios closely monitor D/E, EV, EV/EBITDA, P/B, P/CF, P/E, P/S, and ROE% to evaluate the company's financial performance and valuation trends over time.

Haleos Labs Limited (NSE: HALEOSLABS, BSE: 540679) is currently trading at ₹1286.50, with a market capitalization of ₹3.93B. As a major player in the Health technology sector and Biotechnology industry, Haleos Labs Limited remains a key stock for fundamental analysis using Haleos Labs Limited Ratios.

Haleos Labs Limited Ratios: Valuation Overview

Price to Earnings Ratio (P/E)

The Haleos Labs Limited P/E ratio currently stands at 16.24, making it one of the most tracked metrics in Haleos Labs Limited Ratios.

Historically, the Haleos Labs Limited P/E ratio has shown strong fluctuations:

• 2024: 16.24
• 2023: 22.57
• 2022: 13.71
• 2021: 8.30
• 2020: 11.04

The decline in Haleos Labs Limited P/E ratio suggests improving earnings relative to stock price.

Price to Book Ratio (P/B)

The Haleos Labs Limited P/B ratio reflects how the market values the company's net assets. Current P/B ratio is 1.66.

Historical P/B trend:

• 2024: 1.66
• 2023: 1.16
• 2022: 0.93
• 2021: 1.38

Haleos Labs Limited shows reasonable valuation compared to its asset base.

Price to Sales Ratio (P/S)

The Haleos Labs Limited P/S ratio currently stands at 0.95, an important part of Haleos Labs Limited Ratios for revenue valuation.

Historical P/S ratio:

• 2024: 0.95
• 2023: 0.67
• 2022: 0.50
• 2021: 0.60

The rising Haleos Labs Limited P/S ratio indicates improved revenue valuation by investors.

Haleos Labs Limited Price to Cash Flow Ratio (P/CF)

The Haleos Labs Limited Price to Cash Flow Ratio is a key valuation metric that shows how much investors pay for each unit of cash flow. Current P/CF ratio is 10.96.

Historical Haleos Labs Limited Price to Cash Flow Ratio:

• 2024: 10.96
• 2023: 11.34
• 2022: 13.83
• 2021: 0
• 2020: 4.53

The declining Haleos Labs Limited Price to Cash Flow Ratio suggests improving cash flow strength.

Haleos Labs Limited Enterprise Value Ratios

Enterprise Value (EV)

The Haleos Labs Limited EV currently stands at ₹4.27B, representing the total company valuation including debt.

Historical EV trend:

• 2024: 4.27B
• 2023: 3.21B
• 2022: 2.73B
• 2021: 2.98B

Haleos Labs Limited enterprise value shows long-term growth, reflecting expansion and market confidence.

EV/EBITDA Ratio

The Haleos Labs Limited EV/EBITDA ratio is currently 9.53, a key metric in Haleos Labs Limited Ratios to assess valuation relative to earnings.

Historical EV/EBITDA:

• 2024: 9.53
• 2023: 10.45
• 2022: 9.70
• 2021: 9.16

Stable Haleos Labs Limited EV/EBITDA indicates balanced valuation.

Haleos Labs Limited Financial Strength Ratios

Debt to Equity Ratio (D/E)

The Haleos Labs Limited D/E ratio is currently 0.44, reflecting leverage and financial stability.

Historical D/E:

• 2024: 0.44
• 2023: 0.57
• 2022: 0.60
• 2021: 0.52

Haleos Labs Limited maintains a strong balance sheet with low debt levels.

Return on Equity (ROE %)

The Haleos Labs Limited ROE currently stands at 10.77%, showing profitability and capital efficiency.

Historical ROE:

• 2024: 10.77
• 2023: 5.26
• 2022: 7.15
• 2021: 17.99

Haleos Labs Limited maintains stable profitability levels.

Haleos Labs Limited Ratios Analysis Summary

The Haleos Labs Limited Ratios page provides a comprehensive view of the company's valuation and financial performance. Key metrics such as P/E, P/B, P/S, P/CF, EV, EV/EBITDA, D/E, and ROE help investors understand whether Haleos Labs Limited stock is undervalued, fairly valued, or overvalued.

Tracking Haleos Labs Limited Ratios regularly helps investors make informed decisions based on valuation trends, financial stability, and long-term growth potential.